Aug 26, 2020 Oncolytics Biotech® Doses First Patient in Phase 2 IRENE Study Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer
Aug 10, 2020 Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 40th Annual Growth Conference
Aug 4, 2020 Oncolytics Biotech® Reports 2020 Second Quarter Financial Results and Operational Highlights
Jul 29, 2020 Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights
Jun 25, 2020 Oncolytics Biotech® Announces Investigator Sponsored Phase 2 Trial Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer
Jun 23, 2020 Oncolytics Biotech® Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer
Jun 4, 2020 Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting the Induction of Rapid and Persistent Immune Responses With Systemic Pelareorep Treatment
May 29, 2020 Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual Meeting
May 26, 2020 Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting
